EuropaBio's new White Paper 'Realising the Potential of Personalized Medicine in Europe'

27 October 2014

Biotechnology trade group EuropaBio has issued a new White Paper, aiming to identify the required adaptations in terms of science, drug and diagnostic development programs, as well as in terms of valuing and reimbursement that are essential in order to successfully integrate personalized medicine approaches in health care systems across Europe.

Building on the 2012 EuropaBio position “Personalized Medicine: Status Quo and Challenges,” the current White Paper includes calls for action and policy recommendations to European and national institutions to foster the development of personalized medicine in Europe and help create the right eco-system for it to flourish.

“We believe that personalized medicine can and will be a pillar of a competitive EU health care biotech industry, and a significant contributor to the Union’s ambition of becoming the world’s foremost knowledge-based economy by 2020,” explained Nathalie Moll, EuropaBio secretary general.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK